Intellia Therapeutics Target of Unusually Large Options Trading (NASDAQ:NTLA)

Intellia Therapeutics, Inc. (NASDAQ:NTLA) was the recipient of some unusual options trading on Monday. Stock traders acquired 3,755 call options on the stock. This is an increase of approximately 436% compared to the typical daily volume of 701 call options.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Tudor Investment Corp Et Al purchased a new stake in shares of Intellia Therapeutics during the third quarter worth approximately $242,000. Morgan Stanley increased its position in shares of Intellia Therapeutics by 8.5% during the third quarter. Morgan Stanley now owns 3,090,941 shares of the company’s stock worth $97,736,000 after purchasing an additional 241,734 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Intellia Therapeutics by 18.6% during the third quarter. The Manufacturers Life Insurance Company now owns 68,495 shares of the company’s stock worth $2,166,000 after buying an additional 10,751 shares during the last quarter. Royal Bank of Canada boosted its stake in Intellia Therapeutics by 151.6% during the third quarter. Royal Bank of Canada now owns 83,556 shares of the company’s stock worth $2,641,000 after buying an additional 50,344 shares during the last quarter. Finally, Sectoral Asset Management Inc. boosted its stake in Intellia Therapeutics by 11.4% during the third quarter. Sectoral Asset Management Inc. now owns 112,332 shares of the company’s stock worth $3,552,000 after buying an additional 11,500 shares during the last quarter. 87.72% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Up 7.7 %

Shares of NTLA stock opened at $30.28 on Tuesday. The stock has a 50 day moving average of $29.26 and a 200 day moving average of $37.01. The stock has a market cap of $2.71 billion, a P/E ratio of -5.66 and a beta of 1.76. Intellia Therapeutics has a twelve month low of $22.67 and a twelve month high of $51.94.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.38) EPS for the quarter, beating analysts’ consensus estimates of ($1.52) by $0.14. The business had revenue of $11.99 million during the quarter, compared to analysts’ expectations of $12.45 million. Intellia Therapeutics had a negative return on equity of 40.49% and a negative net margin of 893.34%. The business’s revenue was down 9.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.49) earnings per share. On average, research analysts predict that Intellia Therapeutics will post -5.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Morgan Stanley lowered their price target on Intellia Therapeutics from $90.00 to $85.00 and set an “overweight” rating for the company in a report on Monday, November 13th. Raymond James lowered their price target on Intellia Therapeutics from $78.00 to $57.00 and set an “outperform” rating for the company in a report on Friday, November 10th. The Goldman Sachs Group lowered their price target on Intellia Therapeutics from $157.00 to $136.00 and set a “buy” rating for the company in a report on Friday, November 10th. Royal Bank of Canada decreased their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, November 10th. Finally, Barclays decreased their target price on Intellia Therapeutics from $148.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, August 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $77.70.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.